ivaltinostat

Drug Overview

Ivaltinostat is a highly specialized, novel medication currently being evaluated for the treatment of various challenging cancers and fibrotic diseases. It belongs to a cutting-edge class of medications that work by altering how cancer cells read their own genetic instructions. While it is not yet available at standard pharmacies, it has shown significant promise in ongoing clinical trials.

Here are the key details regarding this medication:

• Generic Name: Ivaltinostat (frequently identified in research literature by its development codes CG-200745 or CG-745).
• US Brand Names: None currently. As an investigational drug, a commercial brand name has not yet been assigned.
• Drug Class: Histone Deacetylase (HDAC) Inhibitor. It is heavily classified as a Targeted Therapy.
• Route of Administration: Primarily administered as an Intravenous (IV) infusion in late-stage clinical trials. An oral capsule formulation (CG-750) has also been evaluated in early safety studies.
• FDA Approval Status: Investigational. Ivaltinostat is not yet fully FDA-approved for general public use. However, it has received “Orphan Drug Designation” from the FDA for specific rare conditions, which helps accelerate its research and development.

What Is It and How Does It Work? (Mechanism of Action)

To understand how ivaltinostat works, it helps to visualize how DNA is stored inside human cells. Your DNA is incredibly long, so to fit inside a cell, it wraps tightly around proteins called “histones,” much like a thread wrapping tightly around a wooden spool.

Certain enzymes in the body, known as Histone Deacetylases (HDACs), control how tightly this DNA thread is wound. When HDAC levels are too high—a common feature in many cancer cells—the DNA is wrapped so tightly that the cell cannot read important “tumor-suppressor” genes. Without these protective genes active, the cancer cells divide out of control and refuse to die naturally.

Ivaltinostat is a Targeted Therapy designed to fix this problem at the molecular level:

• The Chemical Lock: Ivaltinostat features a specific chemical structure (a hydroxamic acid group) that acts like a key, fitting perfectly into the bottom of the HDAC enzyme and binding to a zinc molecule located there. This effectively shuts the HDAC enzyme down.
• Relaxing the DNA: With the HDAC enzyme blocked, the “thread” of DNA relaxes and unwinds.
• Activating Tumor Suppressors: Once the DNA is relaxed, the cell can finally read its protective genes again. Specifically, ivaltinostat triggers the accumulation of a critical tumor-suppressor protein called p53. It also increases the levels of other regulatory proteins like p21 and MDM2.
• Cell Cycle Arrest and Apoptosis: The activation of these protective proteins forces the cancer cell to stop dividing (known as cell cycle arrest at the G2/M phase). Shortly after, the cell initiates apoptosis, which is the programmed death of the faulty cancer cell.

FDA-Approved Clinical Indications

Because ivaltinostat is currently an investigational medication, it does not have official FDA-approved indications for routine clinical practice. However, under its Orphan Drug status and in heavily monitored clinical trials, it is being utilized for the following conditions:

• Oncological Uses (In Clinical Trials):
  • Metastatic Pancreatic Adenocarcinoma: Frequently used in combination with standard chemotherapies like capecitabine or gemcitabine for patients whose tumors have stopped responding to initial treatments.
  • Hepatocellular Carcinoma: A primary type of liver cancer (Orphan Drug Designation).
  • Acute Myeloid Leukemia (AML): A fast-growing blood cancer (Orphan Drug Designation).
  • Prostate Cancer and Non-Small Cell Lung Cancer: Investigated for its ability to make these tumors more sensitive to radiation and standard chemotherapy.
• Non-oncological Uses (In Clinical Trials):
  • Idiopathic Pulmonary Fibrosis (IPF): A severe scarring disease of the lungs (Orphan Drug Designation).
  • Alport Syndrome: A genetic disorder causing progressive kidney damage and fibrosis (Orphan Drug Designation).

Dosage and Administration Protocols

Because ivaltinostat is administered within structured clinical trial environments, dosing is strictly regulated by research protocols. The following table reflects the current standard used in recent Phase II oncology trials (such as those presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium):

Clinical Efficacy and Research Results

Recent clinical data from 2020 through 2025 highlight the growing potential of ivaltinostat, particularly when combined with other cancer-fighting agents.

• Pancreatic Cancer Breakthroughs: Pancreatic ductal adenocarcinoma is notoriously difficult to treat. In a recent Phase Ib/II clinical trial data (NCT05249101) presented in 2025, ivaltinostat was combined with the chemotherapy drug capecitabine for patients whose cancer progressed after initial therapies. This combination demonstrated promising results in a heavily pretreated population, yielding a median overall survival (OS) of up to 8.6 months in select cohorts. It successfully achieved stable disease in many patients with manageable toxicity.
• Enhancing Radiation: Research published in early 2025 regarding prostate cancer revealed that ivaltinostat acts as a potent “radiosensitizer.” By preventing cancer cells from repairing their DNA, the drug significantly increases the cell death caused by standard X-ray radiation therapy.
• Overcoming Drug Resistance: Laboratory and early clinical studies show that ivaltinostat enhances the sensitivity of stubborn, treatment-resistant tumor cells (like cholangiocarcinoma) to standard chemotherapies such as gemcitabine and 5-fluorouracil.

Safety Profile and Side Effects

Black Box Warning: Currently, there is no FDA Black Box Warning for ivaltinostat, as it remains an investigational drug.

Like all treatments that alter cellular function, ivaltinostat carries the risk of side effects. However, early trial data suggest it is generally well-tolerated, especially when compared to traditional, aggressive chemotherapies.

Common Side Effects (>10%)

• Gastrointestinal Distress: Mild to moderate nausea, vomiting, and diarrhea.
• Fatigue: General tiredness and weakness are frequently reported.
• Skin Rash: Mild dermal reactions may occur.
• Mild Cytopenias: A drop in certain blood cells, presenting as mild anemia or easy bruising.

Serious Adverse Events

• Severe Neutropenia: A significant drop in a specific type of white blood cell (neutrophils), which can increase the risk of severe infections.
• Thrombocytopenia: A severe drop in platelets, leading to an elevated risk of bleeding.
• Cardiac Considerations: While less common with ivaltinostat specifically, the broader class of HDAC inhibitors can occasionally cause changes in the heart’s electrical rhythm (QT interval prolongation).

Management Strategies

If severe nausea occurs, oncologists will prescribe strong anti-emetic (anti-nausea) medications before the infusion. For serious drops in blood counts (neutropenia or thrombocytopenia), the medical team will delay the next dose, reduce the overall dosage amount, or administer growth-factor injections to stimulate the bone marrow into producing new blood cells.

Connection to Stem Cell and Regenerative Medicine

Ivaltinostat has a compelling connection to the fields of tissue regeneration and anti-fibrosis. Beyond attacking cancer, HDAC inhibitors are actively researched for their ability to halt “fibrosis” (the aggressive scarring of tissue). In diseases like Alport syndrome or renal fibrosis, damage prompts the body’s cells to overproduce scar tissue, destroying healthy organs. Ivaltinostat targets the TGF-β cellular signaling pathway, which is heavily responsible for this scarring. By calming this pathway, ivaltinostat helps prevent healthy epithelial cells from transforming into scar-producing cells. In the broader landscape of regenerative medicine, medications like ivaltinostat are viewed as potential tools to “reprogram” the cellular environment, protecting healthy stem cells and tissues from being suffocated by fibrotic scar tissue.

Patient Management and Practical Recommendations

For patients participating in clinical trials involving ivaltinostat, careful monitoring and self-care are required to ensure safety and maximize the treatment’s potential benefits.

Pre-treatment Tests to be Performed:

• Complete Blood Count (CBC): To ensure white blood cells, red blood cells, and platelets are at safe levels before infusion.
• Comprehensive Metabolic Panel (CMP): To verify that the liver and kidneys are functioning well enough to process the medication.
• Electrocardiogram (ECG/EKG): A baseline heart scan to monitor the electrical rhythm (QT interval) of the heart.

Precautions During Treatment:

• Because the medication can lower your immune system defenses, you must be highly vigilant about infection risks. Report any fever or chills to your care team immediately.

“Do’s and Don’ts” List:

• DO attend all scheduled blood draw appointments. Your doctor relies on these numbers to safely authorize your next dose.
• DO stay well-hydrated and maintain a balanced diet, especially if experiencing diarrhea or nausea.
• DO practice excellent hand hygiene and avoid crowded areas to prevent catching infections while your white blood cell count fluctuates.
• DON’T take any over-the-counter supplements or herbal remedies without consulting your clinical trial coordinator, as they may interfere with the study drug.
• DON’T ignore minor symptoms. A small fever or mild bleeding gums should be reported to your doctor right away.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Ivaltinostat is an investigational therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, potential drug interactions, and eligibility for clinical trial participation